Back to Search Start Over

Targeting and Blocking B7 Costimulatory Molecules on Antigen-Presenting Cells Using CTLA4Ig-Conjugated Liposomes: In Vitro Characterization and in Vivo Factors Affecting Biodistribution

Authors :
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, 48109-1065; UCSF Diabetes Center, University of California, San Francisco, California, 94143-0540; Department of Microbiology and Immunology, The Transplantation Research Institute, Seoul National University College of Medicine, Seoul, 110-799, Korea
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, 48109-1065
UCSF Diabetes Center, University of California, San Francisco, California, 94143-0540
The Committee on Immunology, Department of Pathology, University of Chicago, Chicago, Illinois, 60637
Ann Arbor
Park, Chung-Gyu
Thiex, Natalie W.
Lee, Kyung-Dall
Bluestone, Jeffery A.
Szot, Gregory L.
Lee, Kyung-Mi
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, 48109-1065; UCSF Diabetes Center, University of California, San Francisco, California, 94143-0540; Department of Microbiology and Immunology, The Transplantation Research Institute, Seoul National University College of Medicine, Seoul, 110-799, Korea
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, 48109-1065
UCSF Diabetes Center, University of California, San Francisco, California, 94143-0540
The Committee on Immunology, Department of Pathology, University of Chicago, Chicago, Illinois, 60637
Ann Arbor
Park, Chung-Gyu
Thiex, Natalie W.
Lee, Kyung-Dall
Bluestone, Jeffery A.
Szot, Gregory L.
Lee, Kyung-Mi
Publication Year :
2006

Abstract

Purpose. CTLA4Ig, a fusion protein of CTLA-4 and Fc of immunoglobulin (Ig) heavy chain, inhibits the essential costimulatory signal for full T cell activation via blocking the interaction between CD28 and B7 molecules and renders T cell nonresponsiveness. CTLA4Ig has been used to control deleterious T cell activation in many experimental systems. We hypothesized that by conjugating CTLA4Ig to liposomes the efficacy of CTLA4Ig could be enhanced through multivalent ligand effect, superior targetability, and modification of the fate of ligated costimulatory molecules.

Details

Database :
OAIster
Notes :
En_US
Publication Type :
Electronic Resource
Accession number :
edsoai.ocn894069974
Document Type :
Electronic Resource